The OJC Episode 6: ASCO Special Episode Part 1

Pinterest LinkedIn Tumblr +

Join us for this Special Episode of The Oncology Journal Club Podcast!  This is the first episode on ASCO 2024 meeting data.

Going beyond the usual presentations, with analysis of practice changing presentations aka ‘The Bangers!’

Join our amazing Hosts, Professor Craig Underhill, Dr. Kate Clarke and Professor Christopher Jackson for the low down.

No other ASCO Commentary is going to combine Spotify playlists and visions of senior oncologists in mankinis with high-level expert analysis. The OJC team are famous for reviewing oncology research with unique humour and entertaining insights.

Don’t forget to check out Part 2!

About The Oncology Journal Club:

We have taken an old concept and updated it with a new format. In each episode, a team of expert contributors will review topical journal papers and interview special guests who are leaders in their fields to help keep you informed of the latest developments on the go.

We hope you enjoy listening and find this a valuable and entertaining resource.



  1. Giuseppe Curigliano et al.  Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). JCO 42, LBA1000-LBA1000(2024). Access online here.
  2. Andrea Cercek et al.  Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer. JCO 42, LBA3512-LBA3512(2024).  Access online here.
  3. Martijn Ruben Meijerink et al. Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial. JCO 42, LBA3501-LBA3501(2024). Access online here.
  4. Rene Adam et al. Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: A prospective multicentric randomized trial (TRANSMET). JCO 42, 3500-3500(2024). Access online here.


  1. Elske C. Gootjes et al. Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer. JCO 42, 2024 (suppl 17; abstr LBA3502). Access online here.
  2. Heinz-Josef Lenz et al. Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW. JCO 42, 2024 (suppl 16; abstr 3503). Access online here.
  3. Jens Hoeppner et al. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial). JCO 42, 2024 (suppl 16; abstr TPS4184).  Access online here.


  1. Chalabi M et al. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2024 Jun 6;390(21):1949-1958.  Access online here.
  2. René Adam et al. Safety and feasibility of chemotherapy followed by liver transplantation for patients with definitely unresectable colorectal liver metastases: insights from the TransMet randomised clinical trial. eClinicalMedicine VOLUME 72, 102608, JUNE 2024. Access online here.
  3. E. Smyth et al. O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study. Annals of Oncology, Volume 34, S182 – S183. Access online here.


Craig Underhill

Professor Craig Underhill

Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on X/Twitter here: @CraigUnderhill

Kate Clarke

Dr. Kate Clarke

Dr Kate Clarke (MBChB (Otago), FRACP) is a proud New Zealander with a real love for beautiful Aotearoa. Dr Clarke continues to work at being Tangata Tiriti. Much of her research and patient advocacy has an equity focus.  Dr Clarke is grateful to her patients, students, whanau and colleagues for the knowledge and awhi they share.  Ehara taku toa, he takitahi, he toa takitini.

Dr Clarke completed her medical training in Otago, Wellington and London. She has a holistic approach and is passionate about patient-centred care, and believes patients can and should play an active role in their healthcare. Her clinical experience covers a broad range of solid tumour malignancies with special clinical interest in colorectal cancer, upper gastrointestinal cancers and breast cancer.

Chris ‘CJ’ Jackson

Professor Christopher Jackson

Chris Jackson is Professor of Medical Oncology at the University of Otago, Dunedin, and a medical oncologist at Dunedin Hospital and Mercy Cancer Care. He specialises in GI cancers and melanoma, teaches medical students and specialists-in-training, and is heavily involved in both national and international cancer policy, leadership and research.

He was previously the medical director of the Cancer Society of NZ, and his advocacy led to the funding of new cancer drugs, to the development of a new national cancer plan, and to the birth of the national cancer agency Te Aho o Te Kahu.  He currently chairs the agency’s clinical committee and serves on the advisory board. In addition, he is on the programme board of the International Cancer Benchmarking Project, and is a founding member of the Common Sense Oncology movement.

Chris is a self-confessed Radiohead tragic, and recent convert to Crossfit (even though you didn’t ask).

Connect with CJ on X/Twitter: @drkiwicj


Rachael Babin

Rachael Babin is Host of The Oncology Podcast, Editor-in-Chief of The Oncology Newsletter,  and Publisher of Oncology News Australia and The Oncology Network.

With a background in oncology communications and academic publishing, Rachael is happiest sitting behind the mic chatting to interesting people about the impact their work makes in oncology.

Connect on Twitter: @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.